Modulators Of Dnm2 Expression Freier; Susan M. ; et al. [Ionis Pharmaceuticals, Inc.]

U.S. Patent Application 20190241896 for Modulators Of Dnm2 Expression

EP0777674B1 - Polynucleotide reagents having nonnucleotidic moieties, and associated methods of synthesis and use - Google Patents

Differential impact of ubiquitous and muscle dynamin 2 isoforms in muscle physiology and centronuclear myopathy

Differential impact of ubiquitous and muscle dynamin 2 isoforms in muscle physiology and centronuclear myopathy

US6268490B1 - Bicyclonucleoside and oligonucleotide analogues - Google Patents

EP0348458B1 - Dna molecules stabilized by modifications of the 3'-terminal phosphodiester linkage and their use as nucleic acid probes and as therapeutic agents to block the expression of specifically targeted genes

EP2341057A2 - Oligonucleotide Analogues - Google Patents

IJMS, Free Full-Text

WO1992005186A1 - Modified internucleoside linkages - Google Patents

Shuling GUO, Director, Doctor of Philosophy, Ionis Pharmaceuticals, Carlsbad, Antisense Drug Discovery

EP0517796B1 - Oligonucleotide analogs - Google Patents

Dynamin 2 (DNM2) as Cause of, and Modifier for, Human Neuromuscular Disease